CD90 是一种免疫组织化学诊断标志物，可用于区分恶性胸膜间皮瘤和肺癌。
CD90 is a diagnostic marker to differentiate between malignant pleural mesothelioma and lung carcinoma with immunohistochemistry.
机构信息
Division of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuo-ku, Chiba 260-8717, Japan; e-mail:
出版信息
Am J Clin Pathol. 2013 Oct;140(4):544-9. doi: 10.1309/AJCPM2Z4NGIIPBGE.
OBJECTIVES
To pathologically distinguish mesothelioma from lung carcinoma, particularly adenocarcinoma.
METHODS
We conducted immunohistochemical analyses on clinical specimens, including 26 cases of mesothelioma, 28 cases of lung adenocarcinoma, and 33 cases of lung squamous cell carcinoma.
RESULTS
We found that CD90 expression was useful in making a differential diagnosis between epithelioid mesothelioma and lung adenocarcinoma, whereas sarcomatoid mesothelioma and lung carcinoma specimens, irrespective of the histologic types, were negative in general. The sensitivity and specificity of CD90 expression in epithelioid mesothelioma and lung adenocarcinoma were comparable to those of well-established markers used for the differential diagnosis.
CONCLUSIONS
These data collectively indicate that CD90 is a novel diagnostic marker that contributes to a diagnosis of epithelioid mesothelioma.
目的
从病理学上区分间皮瘤与肺癌，特别是腺癌。
方法
我们对包括 26 例间皮瘤、28 例肺腺癌和 33 例肺鳞癌在内的临床标本进行了免疫组织化学分析。
结果
我们发现 CD90 的表达有助于鉴别上皮样间皮瘤和肺腺癌，而肉瘤样间皮瘤和肺癌标本通常均为阴性，无论组织学类型如何。CD90 在上皮样间皮瘤和肺腺癌中的敏感性和特异性与用于鉴别诊断的公认标志物相当。
结论
这些数据表明 CD90 是一种新的诊断标志物，有助于诊断上皮样间皮瘤。
Zotero 插件